Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin

Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin: Retrospective Study in Patients Followed at the CHRU of Brest

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04109404

Acronym

MAP

Enrollment

110

Registered

2019-09-30

Start date

2019-02-25

Completion date

2019-06-01

Last updated

2019-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningioma

Keywords

meningioma,, progestin,, cyproterone acetate

Brief summary

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Detailed description

Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* minimum 18 years * medical follow up in CHRU of Brest * treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception * meningioma after treatement by progestin or CYPROTERONE ACETATE

Exclusion criteria

* history ofbreast cancer * history of cerebral radiotherapy * history of neurofibromatosis * meningioma before treatement by progestin or CYPROTERONE ACETATE * minor patient

Design outcomes

Primary

Measure	Time frame	Description
Diagnosis of meningiomas caracteristics	12 months	meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description

Secondary

Measure	Time frame	Description
prescription status of progestogenic treatment	12 months	indications, duration of treatment, name and type of treatment

Countries

France

Outcome results